Abstract 214P
Background
Urothelial carcinoma (UC), including upper tract UC (UTUC) and UC of the bladder (UCB), is one of the most common malignancies worldwide. The current standard methods for diagnosis and monitoring of UC are often invasive and/or lack sensitivity and specificity. Emerging evidence has shown that urinary RNAs could potentially serve as promising biomarkers for UC diagnosis. In this study, we intended to develop and validate an accurate and noninvasive urine RNA test for UC diagnosis and monitoring.
Methods
Gene expression profiling of our previously reported 32 RNA targets were analyzed TaqMan qPCR arrays. We pooled all samples analyzed before to obtain a larger training set and develop a diagnostic gene panel. The identified gene panel was then validated in a large-scale independent cohort of 752 patients. Voided urine specimens were prospectively collected at 3 hospitals from subjects scheduled for tumor surgery or endoscopy for the urinary tract due to suspicious symptoms. The sensitivity and specificity of the gene panel were evaluated using endoscopy and/or histologic diagnosis as a reference.
Results
An eight-gene panel (CA9, CCL18, ERBB2, IGF2, MMP12, PPP1R14D, SGK2 and SWINGN) was developed. In the prospective cohort, the gene panel achieved 93.4%overall accuracy (702/752), 92.3% sensitivity (275/298) and 94.1% specificity (427/454). High sensitivity was maintained in low grade (89.9%, 62/69), early stage (88.5%, 115/130) and residual tumors (89.5%, 34/38). Notably, the gene panel accurately detected UTUCs with 97.3% (36/37) sensitivity, indicating that urinary RNA targets selected here were relevant markers for both UTUC and UCB. Besides, the specificity among other malignancies like prostate cancer, renal cancer, etc. reached 94.5% (173/183). With respect to surveillance, the gene panel showed 88.6% sensitivity and 98.2% specificity for detecting recurrences in 136 patients.
Conclusions
In summary, the eight-gene urine test showed superior sensitivity and specificity for diagnosis of UCs across all tumor stages, grades and sites, hence might represent a promising tool for noninvasive UC detection and surveillance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Canhelp Genomics.
Disclosure
Y. Wo, Z. Luo, J. Chen, Q. Xu: Financial Interests, Personal, Full or part-time Employment: Canhelp Genomics. All other authors have declared no conflicts of interest.
Resources from the same session
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract